Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Breast Cancer Metastasis Depends on Expression of Leader Cell Protein

By BiotechDaily International staff writers
Posted on 24 Dec 2013
Image: A breast tumor (blue) uses leader cells (green) to invade muscle tissue (red) in a mouse (Photo courtesy of Dr. Kevin Cheung, Cell).
Image: A breast tumor (blue) uses leader cells (green) to invade muscle tissue (red) in a mouse (Photo courtesy of Dr. Kevin Cheung, Cell).
Cell biologists have identified a protein that they regard as a potential drug target in a unique class of breast cancer cells that lead the process of metastasis into surrounding tissues.

Carcinomas typically migrate into normal tissues as a cohesive multicellular unit, a process termed collective invasion. It has been unclear how different subpopulations of cancer cells contributed to this process.

Investigators at Johns Hopkins University (Baltimore, MD, USA) developed three-dimensional organoid assays to identify the most invasive cancer cells in primary breast tumors. They reported in the December 12, 2013, online edition of the journal Cell that collective invasion was led by specialized cancer cells (leader cells) that were defined by their expression of basal epithelial genes, such as cytokeratin-14 (K14) and p63. Furthermore, examination of human tumor samples showed that K14-expressing cells led collective invasion in the major human breast cancer subtypes.

To confirm the role of K14 in the invasive process, the investigators used gene therapy techniques to block its expression in some tumor lines. Cancer cells with blocked K14 expression and similar but untreated cancer cells were then implanted into different sites on the same mouse. Examination of the resulting tumors showed that leader cells were present in the K14-expressing tumors and were leading vigorous invasions into normal tissue. In the tumors with blocked K14 expression essentially no invasions occurred.

"Metastasis is what most threatens breast cancer patients, and we have found a way to stop the first part of the process in mice," said senior author Dr. Andrew Ewald, assistant professor of cell biology at Johns Hopkins University. "We are still several years away from being able to use these insights to help patients with breast cancer, but we now know which tumor cells are the most dangerous, and we know some of the proteins they rely on to do their dirty work. Just a few leader cells are sufficient to start the process of metastasis, and they require K14 to lead the invasion."

Related Links:

Johns Hopkins University



comments powered by Disqus

Channels

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.